DongKoo Bio & Pharma Co., Ltd. (KOSDAQ:006620)

DongKoo Bio & Pharma Revenue

DongKoo Bio & Pharma had revenue of 59.48B KRW in the quarter ending June 30, 2026, a decrease of -1.07%. This brings the company's total for the last twelve months to 241.43B, down -0.46% year-over-year. In the year 2025, DongKoo Bio & Pharma had annual revenue of 242.69B, down -2.64%. That makes DongKoo Bio & Pharma the 18,132nd largest company in the world by revenue and 931st in South Korea.

• Revenue (ttm): 241.43B
• Revenue Growth: -0.46%
• P/S Ratio: 0.37
• Revenue / Employee: 630.38M
• Employees: 383
• Market Cap: 89.24B

Revenue Chart

Chart

Chart

Revenue by Segment

By Segment

Chart

• Pharmaceutical manufacturing industry 230.84B 94.3%
• New Technology Business Financing 12.34B 5.0%
• Pharmaceutical marketing agency 1.60B 0.7%

By Geography

Chart

• South Korea 226.08B 98.1%
• Overseas 4.27B 1.9%

Fiscal year ended Dec 31, 2025 See the full DongKoo Bio & Pharma breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	242.69B	-6.59B	-2.64%
Dec 31, 2024	249.27B	33.59B	15.57%
Dec 31, 2023	215.69B	20.70B	10.62%
Dec 31, 2022	194.99B	39.84B	25.68%
Dec 31, 2021	155.15B	15.93B	11.45%

Data Source: S&P Global Market Intelligence Last updated: Aug 12, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Oct 20, 2026

Data Sources Report a data error